JP2005516035A5 - - Google Patents

Download PDF

Info

Publication number
JP2005516035A5
JP2005516035A5 JP2003561625A JP2003561625A JP2005516035A5 JP 2005516035 A5 JP2005516035 A5 JP 2005516035A5 JP 2003561625 A JP2003561625 A JP 2003561625A JP 2003561625 A JP2003561625 A JP 2003561625A JP 2005516035 A5 JP2005516035 A5 JP 2005516035A5
Authority
JP
Japan
Prior art keywords
melagatran
medicament
kit
pharmaceutically acceptable
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003561625A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005516035A (ja
Filing date
Publication date
Priority claimed from SE0200198A external-priority patent/SE0200198D0/xx
Application filed filed Critical
Publication of JP2005516035A publication Critical patent/JP2005516035A/ja
Publication of JP2005516035A5 publication Critical patent/JP2005516035A5/ja
Pending legal-status Critical Current

Links

JP2003561625A 2002-01-23 2003-01-21 I型糖尿病の処置に用いる医薬の製造のための、メラガトランの使用 Pending JP2005516035A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0200198A SE0200198D0 (sv) 2002-01-23 2002-01-23 New use
PCT/SE2003/000087 WO2003061682A1 (en) 2002-01-23 2003-01-21 The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus

Publications (2)

Publication Number Publication Date
JP2005516035A JP2005516035A (ja) 2005-06-02
JP2005516035A5 true JP2005516035A5 (OSRAM) 2006-03-09

Family

ID=20286751

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003561625A Pending JP2005516035A (ja) 2002-01-23 2003-01-21 I型糖尿病の処置に用いる医薬の製造のための、メラガトランの使用

Country Status (14)

Country Link
US (2) US7045502B2 (OSRAM)
EP (1) EP1469874A1 (OSRAM)
JP (1) JP2005516035A (OSRAM)
KR (1) KR20040075096A (OSRAM)
CN (1) CN100430089C (OSRAM)
BR (1) BR0306798A (OSRAM)
CA (1) CA2472241A1 (OSRAM)
IL (1) IL162853A0 (OSRAM)
MX (1) MXPA04007192A (OSRAM)
NO (1) NO20043483L (OSRAM)
NZ (1) NZ533749A (OSRAM)
SE (1) SE0200198D0 (OSRAM)
WO (1) WO2003061682A1 (OSRAM)
ZA (1) ZA200405342B (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0200198D0 (sv) * 2002-01-23 2002-01-23 Astrazeneca Ab New use
JP6155187B2 (ja) 2010-03-30 2017-06-28 ヴァーセオン コーポレイション トロンビンの阻害剤としての多置換芳香族化合物
WO2014145986A1 (en) 2013-03-15 2014-09-18 Verseon, Inc. Multisubstituted aromatic compounds as serine protease inhibitors
ES2791749T3 (es) 2013-03-15 2020-11-05 Verseon Corp Halogenopirazoles como inhibidores de la trombina
KR20170048410A (ko) 2014-09-17 2017-05-08 베르선 코포레이션 세린 프로테아제 저해제로서의 피라졸릴-치환된 피리돈 화합물
AU2016224974B2 (en) 2015-02-27 2019-09-26 Verseon Corporation Substituted pyrazole compounds as serine protease inhibitors
IL280078B2 (en) 2018-07-13 2024-04-01 Verseon Int Corporation Thrombin inhibitors, formulations, and uses thereof
AU2022325955A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
JP2025508720A (ja) 2022-02-17 2025-04-10 サナ バイオテクノロジー,インコーポレイテッド 遺伝子操作されたcd47タンパク質及びその使用関連出願の相互参照
AU2024264889A1 (en) 2023-05-03 2025-11-13 Sana Biotechnology, Inc. Methods of dosing and administration of engineered islet cells
CN121604968A (zh) 2023-05-22 2026-03-03 萨那生物科技公司 递送胰岛细胞的方法及相关方法
IL326710A (en) 2023-08-23 2026-04-01 Sana Biotechnology Inc Modified CD47 proteins and their uses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301916D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
TW541316B (en) 1995-12-21 2003-07-11 Astrazeneca Ab Prodrugs of thrombin inhibitors
SE9900070D0 (sv) 1999-01-13 1999-01-13 Astra Ab New use
SE523817C2 (sv) 1999-02-05 2004-05-18 Corline Systems Ab Användning av ett koagulationsförebyggande ämne i samband med transplantation av insulinproducerande celler
US6462021B1 (en) 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
SE0200198D0 (sv) * 2002-01-23 2002-01-23 Astrazeneca Ab New use

Similar Documents

Publication Publication Date Title
JP2007519649A5 (OSRAM)
JP2004538303A5 (OSRAM)
JP2007506775A5 (OSRAM)
JP2006515587A5 (OSRAM)
JP2008510691A5 (OSRAM)
JP2006143737A5 (OSRAM)
JP2004534057A5 (OSRAM)
JP2009500423A5 (OSRAM)
TW200528097A (en) Novel thiazolidin-4-one derivatives
JP2005526696A5 (OSRAM)
CA2513092A1 (en) Compounds for the treatment of metabolic disorders
CA2522738A1 (en) Compounds for the treatment of metabolic disorders
CA2521621A1 (en) Compounds for the treatment of metabolic disorders
JP2008512408A5 (OSRAM)
JPH08504201A (ja) 抗うつ作用を有する医薬組成物としての2‐アミノ‐6‐n‐プロピル‐アミノ‐4,5,6,7‐テトラヒドロベンゾチアゾールの使用
CA2621404A1 (en) Novel heterobicyclic derivatives
RU2004132856A (ru) Фармацевтический препарат с модифицированным высвобождением
JP2007507494A5 (OSRAM)
JP2006502187A5 (OSRAM)
JP2002519425A5 (OSRAM)
JP2022505989A5 (OSRAM)
JP2006510606A5 (OSRAM)
JP2006510658A5 (OSRAM)
JPWO2013081154A1 (ja) キナーゼ阻害剤の副作用低減剤
JP2004525178A5 (OSRAM)